Steven R. Patierno, Ph.D.

Duke Cancer Institute

Joining Duke in 2012, Dr. Patierno serves as Deputy Director of the Duke Cancer Institute, Professor of Medicine, Professor of Pharmacology and Cancer  Biology, and Professor of Community and Family Medicine, and as Director of Cancer Control, Healthcare Delivery and Population Sciences, as well as Cancer Supportive Care and Survivorship Services. Prior to joining Duke, Dr.Patierno served as Executive Director of The George Washington University Cancer Center, the Vivian Gill Distinguished Professor of Oncology and Professor of Pharmacology and Physiology, Genetics and Urology in the GWU School of Medicine and Health Sciences. His prior training includes a B.S. in Pharmacy from the University of Connecticut, a PhD in molecular pharmacology from the Graduate School of Biomedical Science, University of Texas Health Science Center-MD Anderson Cancer Institute in Houston Texas, and an NIH-funded postdoctoral fellowship at the University of Southern California (USC) Norris Comprehensive Cancer Center in molecular oncology and carcinogenesis. Dr.Patierno’s basic science and translational research laboratory has been funded continuously by the NIH, the NCI and Department of Defense for nearly 25 years and he has published more than 130 peer-reviewed cancer research papers on molecular carcinogenesis, metastasis, cancer pharmacology and most recently on the genomics, epigenomics, transcriptomics and biology of cancer disparities. In addition, he has led a number of large, multi-institutional, patient-centered, community-based and cancer healthcare delivery grants from the NCI, CDC, numerous foundations, industry, and the DC Cancer Consortium addressing cancer disparities, patient navigation, prevention, control, education, outreach, and survivorship. This includes serving as PI to the DC arm of the NCI-funded, multi-institutional Patient Navigation Research Program, and DC City-wide Patient Navigation Network.The Duke Cancer Institute is a top-ranked NCI-designated Comprehensive Cancer Center dedicated to providing leading-edge compassionate care from diagnosis to treatment to survivorship, advancing multi- and trans-disciplinary cancer research across the full cancer research continuum, and engaging in authentic prevention and community health programming. DCI is one of the original eight NCI-designated comprehensive cancer centers, with more than 75,000 patient visits and 7500 new cancer diagnoses annually, with nearly 1000 active clinical trials. DCI includes more than 350 investigators with more than $250 million in annual cancer research funding.